63 related articles for article (PubMed ID: 35697228)
21. A road map for the treatment of pediatric diffuse midline glioma.
Koschmann C; Al-Holou WN; Alonso MM; Anastas J; Bandopadhayay P; Barron T; Becher O; Cartaxo R; Castro MG; Chung C; Clausen M; Dang D; Doherty R; Duchatel R; Dun M; Filbin M; Franson A; Galban S; Garcia Moure M; Garton H; Gowda P; Marques JG; Hawkins C; Heath A; Hulleman E; Ji S; Jones C; Kilburn L; Kline C; Koldobskiy MA; Lim D; Lowenstein PR; Lu QR; Lum J; Mack S; Magge S; Marini B; Martin D; Marupudi N; Messinger D; Mody R; Morgan M; Mota M; Muraszko K; Mueller S; Natarajan SK; Nazarian J; Niculcea M; Nuechterlein N; Okada H; Opipari V; Pai MP; Pal S; Peterson E; Phoenix T; Prensner JR; Pun M; Raju GP; Reitman ZJ; Resnick A; Rogawski D; Saratsis A; Sbergio SG; Souweidane M; Stafford JM; Tzaridis T; Venkataraman S; Vittorio O; Wadden J; Wahl D; Wechsler-Reya RJ; Yadav VN; Zhang X; Zhang Q; Venneti S
Cancer Cell; 2024 Jan; 42(1):1-5. PubMed ID: 38039965
[TBL] [Abstract][Full Text] [Related]
22. A first-in-human peptide vaccine targeting H3K27M; encouraging early findings in 8 adults with diffuse midline glioma.
Hotchkiss KM; Cho EJ; Khasraw M
Neuro Oncol; 2024 Jan; 26(1):5-6. PubMed ID: 37930280
[No Abstract] [Full Text] [Related]
23. Classification of unilateral thalamic gliomas predicts tumor resection and patient's survival: a single center retrospective study.
Que T; Li Z; Zheng H; Tan JE; Yuan X; Yi G; Fang L; Nie J; Yin Y; Xu H; Zheng X; Liu J; Zhang XA; Qi S; Huang G
J Neurosurg Sci; 2022 Apr; ():. PubMed ID: 35416455
[TBL] [Abstract][Full Text] [Related]
24. Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon.
Dun MD; Odia Y; Arrillaga-Romany I
Neuro Oncol; 2024 May; 26(Supplement_2):S89-S91. PubMed ID: 38108088
[No Abstract] [Full Text] [Related]
25. Editorial. Prolonged survival in diffuse midline gliomas: a socioeconomic status symbol or a marker of good supportive care?
Wedemeyer MA; Leonard J
J Neurosurg Pediatr; 2024 Mar; 33(6):505-506. PubMed ID: 38489809
[No Abstract] [Full Text] [Related]
26. A non-midline unclassified glioneuronal tumor with H3K27M mutation enlarging the spectrum of CNS tumors H3K27ME3-altered.
Aboubakr O; Senova S; Kauv P; Castel D; Ajlil Y; Saffroy R; Appay R; Métais A; Hasty L; Varlet P; Tauziède-Espariat A
J Neuropathol Exp Neurol; 2024 Apr; ():. PubMed ID: 38652922
[No Abstract] [Full Text] [Related]
27. [Diffuse midline glioma with H3K27 alteration in adults: a clinicopathological analysis].
Yang QY; Li MN; Chen TY; Liu C; Li X; Shi ZM; Pan MH
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):376-383. PubMed ID: 36973199
[No Abstract] [Full Text] [Related]
28. Advancements in Image-Based Models for High-Grade Gliomas Might Be Accelerated.
Frosina G
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672647
[TBL] [Abstract][Full Text] [Related]
29. National trends in the treatment of adult diffuse midline gliomas: a rare clinical scenario.
Desai J; Rajkumar S; Shepard MJ; Herbst J; Karlovits SM; Hasan S; Horne ZD; Wegner RE
J Neurooncol; 2024 Jun; 168(2):269-274. PubMed ID: 38630388
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors analysis of diffuse midline glioma.
Jiang J; Li WB; Xiao SW
J Neurooncol; 2024 Apr; 167(2):285-292. PubMed ID: 38381257
[TBL] [Abstract][Full Text] [Related]
31. Diffuse Midline H3K27-Altered Gliomas in the Spinal Cord: A Systematic Review.
Watanabe G; Wong JM; Estes B; Khan MF; Ogasawara C; Umana GE; Martin AR; Bloch O; Palmisciano P
J Neurooncol; 2024 Feb; 166(3):379-394. PubMed ID: 38342826
[TBL] [Abstract][Full Text] [Related]
32. Deep Learning for the Prediction of the Survival of Midline Diffuse Glioma with an H3K27M Alteration.
Huang B; Chen T; Zhang Y; Mao Q; Ju Y; Liu Y; Wang X; Li Q; Lei Y; Ren Y
Brain Sci; 2023 Oct; 13(10):. PubMed ID: 37891850
[TBL] [Abstract][Full Text] [Related]
33. Clinical Features and Prognosis of Diffuse Midline Glioma: A Series of 24 Cases.
Jang SW; Song SW; Kim YH; Cho YH; Hong SH; Kim JH; Ra YS; Chong S
Brain Tumor Res Treat; 2022 Oct; 10(4):255-264. PubMed ID: 36347640
[TBL] [Abstract][Full Text] [Related]
34. Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors.
Bozkurt SU; Dagcinar A; Tanrikulu B; Comunoglu N; Meydan BC; Ozek M; Oz B
Childs Nerv Syst; 2018 Jan; 34(1):107-116. PubMed ID: 29063957
[TBL] [Abstract][Full Text] [Related]
35. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
[No Abstract] [Full Text] [Related]
36. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
[TBL] [Abstract][Full Text] [Related]
37. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
Vuong HG; Ngo TNM; Le HT; Dunn IF
J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
[TBL] [Abstract][Full Text] [Related]
38. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
[TBL] [Abstract][Full Text] [Related]
39. H3K27M-Altered Diffuse Midline Gliomas Among Adult Patients: A Systematic Review of Clinical Features and Survival Analysis.
Bin-Alamer O; Jimenez AE; Azad TD; Bettegowda C; Mukherjee D
World Neurosurg; 2022 Sep; 165():e251-e264. PubMed ID: 35697228
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
